Orion saw the highest growth of 149% in patent filings and 124% in grants in January in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 149% and grants by 124%. GlobalData’s DataBook provides a comprehensive analysis of Orion‘s patent filings and grants. Buy the databook here.
Orion has been focused on protecting inventions in European Patent Office(EPO) with seven publications in Q1 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 33% of filings. The European Patent Office(EPO), Chile(CL), Denmark(DK), and Finland(FI) patent Office are among the top ten patent offices where Orion is filings its patents. Among the top granted patent authorities, Orion has 25% of its grants in Finland(FI) and 25% in Croatia(HR).
F. Hoffmann-La Roche could be the strongest competitor for Orion
Patents related to electronic medical record (emr) systems and healthtech lead Orion's portfolio
Orion has the highest number of patents in electronic medical record (emr) systems followed by, healthtech and connected care. For electronic medical record (emr) systems, nearly 10% of patents were filed and no patents were granted in Q1 2024.
Prostate cancer related patents lead Orion portfolio followed by breast cancer, and emesis (vomiting)
Orion has highest number of patents in prostate cancer followed by breast cancer, emesis (vomiting), packaging, and pain. For prostate cancer, nearly 32% of patents were filed and 14% of patents were granted in Q1 2024.
For comprehensive analysis of Orion's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.